131 related articles for article (PubMed ID: 1901535)
1. Comparative antimicrobial activity of ceftibuten against multiply-resistant microorganisms from Belgium.
Verbist L; Jacobs J; Hens K
Diagn Microbiol Infect Dis; 1991; 14(1):53-61. PubMed ID: 1901535
[TBL] [Abstract][Full Text] [Related]
2. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.
Bauernfeind A
Diagn Microbiol Infect Dis; 1991; 14(1):63-74. PubMed ID: 2013211
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Bauernfeind A; Jungwirth R
Infection; 1991; 19(5):353-62. PubMed ID: 1800377
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of RO 15-8074 and RO 19-5247.
Valle T; Jalanko E; Scheinin L; Renkonen OV
Eur J Clin Microbiol; 1987 Apr; 6(2):167-9. PubMed ID: 3109897
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
Jones RN; Barry AL
Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
[TBL] [Abstract][Full Text] [Related]
6. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074.
Aldridge KE; Schiro DD; Sanders CV
Eur J Clin Microbiol; 1987 Oct; 6(5):564-9. PubMed ID: 3436316
[TBL] [Abstract][Full Text] [Related]
8. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
Wise R; Andrews JM; Ashby JP; Thornber D
Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of Ro 15-8074 and Ro 19-5247 in comparison to cefaclor and cefalexin.
Simon C
Infection; 1987; 15(2):122-4. PubMed ID: 3596808
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).
Neu HC; Chin NX; Labthavikul P
Antimicrob Agents Chemother; 1986 Sep; 30(3):423-8. PubMed ID: 3490827
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of tigemonam, a novel oral monobactam.
Tanaka SK; Summerill RA; Minassian BF; Bush K; Visnic DA; Bonner DP; Sykes RB
Antimicrob Agents Chemother; 1987 Feb; 31(2):219-25. PubMed ID: 3105448
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
Matsuzaki K; Yoshimori K; Shikano M; Watabe E; Sato Y; Hasegawa M; Kobayashi I; Yamanaka N
Jpn J Antibiot; 2003 Jun; 56(3):171-9. PubMed ID: 12942788
[TBL] [Abstract][Full Text] [Related]
13. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
Abe T; Fukuoka T; Sato Y; Ito K; Sei M
Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
Hiraoka M; Masuyoshi S; Tomatsu K; Inoue M; Mitsuhashi S
Eur J Clin Microbiol; 1987 Oct; 6(5):559-63. PubMed ID: 3501756
[TBL] [Abstract][Full Text] [Related]
15. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
Jones RN; Thornsberry C
Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH
J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176
[TBL] [Abstract][Full Text] [Related]
17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of Ro 19-5247 and Ro 15-8074, new oral cephalosporins.
Fass RJ; Helsel VL
Antimicrob Agents Chemother; 1986 Sep; 30(3):429-34. PubMed ID: 3777906
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
Doern GV
Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1988 Oct; 32(10):1576-82. PubMed ID: 3190185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
